Telmisartan, an AT1 receptor antagonist, significantly inhibited the growth of the non-small cell lung cancer (NSCLC) A549 cell line, in a time- and dose-dependent manner and led to an increase of the pro-apoptotic proteins caspase-3 and Bcl-xL [70]. The gene discussed is AGTR1; the disease is non-small cell lung carcinoma.